arrow
E

Elizabeth A. Griffiths

Roswell Park Comprehensive Cancer Center
H指数:49
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响:考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

2026-08-280
PRE
Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)

多组学验证骨髓增生异常综合征(MDS)分子分类的临床相关性

2026-07-280
OAAI
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

高风险骨髓增生异常综合征/新生物患者接受去甲基化药物+维奈克拉治疗后的结局分析——国际骨髓增生异常综合征(icMDS)VALIDATE数据库分析

2026-06-290
OAAI
Decitabine-cedazuridine in patients with MDS and TP53 mutations

地西他滨-西达佐鲁定在伴TP53突变的患者中的研究

2025-11-140
OAAI
Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection

COVID-19疫苗接种与SARS-CoV-2感染后心血管并发症风险的相关性:一项针对癌症患者的国际队列研究

2025-04-010
OAAI
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/SyndromesdRecommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

骨髓增生异常肿瘤/综合征的诊断和分类的当代方法国际骨髓增生异常肿瘤/综合征联合会 (MDS [icMDS]) 的建议

2024-12-011
PRE
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis
2024-07-011
OAAI
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
2024-04-232
OAAI
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study

癌症转移对新型冠状病毒肺炎结局的影响: 基于新型冠状病毒肺炎和癌症协会注册的回顾性队列研究

CANCER
IF5.1
2024-02-200
PRE
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
2024-01-0115
PRE
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

骨髓增生异常综合征/肿瘤 (MDS) 的分类,风险分层和反应评估: 代表国际MDS联合会 (icMDS) 的最新报告

2023-11-019
OAAI